Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Geneart wins new European patent
The patent protects a procedure for the selective identification of improved protein variants in Austria, Belgium, Switzerland, Spain, France, the UK, Italy, Luxemburg, the Netherlands, Sweden and Germany.
The patent protects a procedure for the selective identification of improved protein variants in Austria, Belgium, Switzerland, Spain, France, the UK, Italy, Luxemburg, the Netherlands, Sweden and Germany.
The FDA indicated in its letter that they cannot approve the application for iclaprim in its current form and that additional clinical data are required to demonstrate efficacy
The latest patent protects the central concept of having all components of the x-ray system in the same enclosure. This concept led to the development of the world’s
A total of 711 patients have been randomized in 123 clinical centers in the US, Europe and South America for Ardis 1. This study is the first of
The grant will support a total of nearly $200 million investment by Agfa HealthCare in its Ontario operations, creating 100 new positions and re-investing in 276 existing jobs.
According to the company, cartridges for E3+, EC4+ and 6+ aid the clinician in assessing a patient’s metabolic state within a few minutes. The glucose cartridge quickly delivers
The CE Mark enables Access Scientific to sell the MicroAccess Wand broadly around the globe. The device has already received the FDA clearance. According to the company, the
Mr Peacock is president and CEO of Alba Therapeutics, and has also been a venture partner with SV Life Sciences since May 2006. Mr Peacock currently serves as
GlaxoSmithKline (GSK) said that it is the first time the European Commission has approved a non-prescription product for weight loss. The centrally approved marketing authorization means GSK can
Mr Keltjens will succeed Eamonn Hobbs, a co-founder of AngioDynamics, who has led the company for the past 21 years and will become vice chairman of the board